Final Rule Puts Pharma Patent Licensing Agreements Under FTC Microscope

Drugmakers will soon have to seek Federal Trade Commission antitrust review for all proposed licensing agreements for “exclusive” patent rights. The rule expands the meaning of “exclusive patent rights” to adapt to increasingly complicated licensing deals in which drug companies transfer most, but not all, of the patent rights to “make, use, and sell” under an exclusive license.
Drug Industry Daily